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Purpose: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) features of breast
cancer according to intrinsic subtypes and to investigate whether the MRI and immunohistochemical findings were
related to neoadjuvant chemotherapy (NAC) effects.
Materials and methods: The MRI in 116 women with breast cancers who underwent NAC was reviewed. The
mass margin, presence of intratumoral necrosis, tumor extension around the mass, relative signal enhancement
(RSE), and kinetic curve pattern were analyzed. We investigated the possible correlations between MRI findings and
the effects of NAC.
Results: An irregular mass margin was significantly associated with luminal-A cancers, while a smooth mass margin
was associated with human epidermal growth factor receptor2 (HER2) cancers. Intratumoral necrosis was significantly
associated with triple-negative cancers. Tumor extension around the mass was significantly infrequent in luminal-B
cancers and frequent in HER2 cancers. Luminal-B and HER2 cancers showed a significantly higher RSE at 2 min than
Luminal-A cancers. Estrogen receptor (ER)-positive cancers, HER2-negative cancers, and presence of intratumoral
necrosis were significantly associated with the NAC non-response.
Conclusions: Several MR features can be used to predict the intrinsic subtype of breast cancers. ER-positivity,
HER2-negativity, and presence of intratumoral necrosis were significantly associated with NAC non-response.
Keywords: Magnetic resonance imaging; Breast cancer; Intrinsic subtype; Neoadjuvant chemotherapyIntroduction
It has become clear that breast cancers can be divided
into biologically different intrinsic subtypes by gene ex-
pression analysis (Perou et al. 2000; Sorlie et al. 2001;
Perou & Borresen-Dale 2011; Brenton et al. 2005). In
clinical practice, it is common to determine the patient’s
intrinsic subtype using an immunohistochemical technique
(Tamimi et al. 2008), and a therapeutic plan is formed based
on each intrinsic subtype. From this trend, diagnosing* Correspondence: hirokok@med.kanazawa-u.ac.jp
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in mind is becoming a more widespread practice.
Neoadjuvant chemotherapy (NAC) has been the stand-
ard treatment for locally-advanced breast cancer (Makhoul
& Kiwan 2011). NAC is mainly designed to reduce the
tumor size, thereby permitting breast-conserving surgery
(Liu et al. 2010). Other advantages of NAC are that sys-
temic therapy may be initiated earlier, and it enables evalu-
ation of a patient’s response to chemotherapy (Kaufmann
et al. 2007; Kaufmann et al. 2006). Conversely, a NAC-
related disadvantage is the delay of surgical treatment in
patients who do not respond to chemotherapy. If we can
predict the final chemotherapeutic response during earlier
NAC courses, an earlier and optimized treatment regimens is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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et al. 2002; Montagna et al. 2010).
The purpose of this study was to evaluate the magnetic
resonance imaging (MRI) features of breast cancer accord-
ing to the intrinsic subtypes, and to investigate whether the




Kanazawa University Medical Ethical Review Board ap-
proved this retrospective study, and the requirement for
informed consent was waived. We enrolled patients with
breast cancer who underwent NAC at our hospital be-
tween March 2008 and January 2013. A core biopsy of
the tumor was performed prior to NAC to determine the
histological diagnosis, hormone receptor status, human
epidermal growth factor receptor 2 (HER2) overexpression
status, and Ki-67 labeling index. We divided patients into
five intrinsic subtypes. The subjects included 116 women
(24 luminal A, 15 luminal B, 14 luminal-HER2, 23 HER2,
and 40 triple-negative cancers) (Table 1). All cases showed
mass formation and the mean maximal tumor size was 28
mm (range, 13-69 mm). The Ki-67 labeling index has not
measured for the initial 42 cases; therefore, we judged lu-
minal A or B status according to proliferative parameters
such as the nuclear grade.
The therapeutic schedule and treatment plan were ex-
plained to the patient, and informed consent was obtained
from all patients. The standard protocol is four cycles of a
combination of 100 mg/m2 epirubicin, 500 mg/m2 cyclo-
phosphamide, and 500 mg/m2 fluorouracil every 3 weeks
(FEC4), followed by four cycles of 75 mg/m2 doxetaxel
every 3 weeks (DOC4).
Magnetic resonance imaging
MRI was performed on a 3.0 T magnet (Signa HDxt 3.0 T,
GE Healthcare, Tokyo, Japan) using an eight-channel breast
phased array coil. The patients underwent imaging while
in the prone position. Sagittal T1-weighted images were
obtained using a spin-echo sequence (TR/TE [repetition
time/echo time], 500/7.6 ms; FOV [field of view], 20 cm;
section thickness, 4 mm; gap, 1 mm; matrix, 320 × 192;Table 1 Substitutional definition of intrinsic subtype
Intrinsic subtype ER PgR HER2 Ki-67
Luminal A + +/− - <14%
Luminal B + +/− - ≧14%
Luminal-HER2 + +/− + any
HER2 - - + any
Triple-negative - - - any
ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal
growth factor receptor 2.NEX [number of excitation], 2). Sagittal T2-weighted im-
ages with fat suppression were obtained using a fast spin-
echo sequence (TR/TE, 3834/102 ms; FOV, 20 cm; section
thickness, 4 mm; gap, 1 mm; matrix, 288 × 224; NEX, 2;
acquisition time, 2 min and 39 s). Axial diffusion-weighted
images of both breasts were obtained at b values of 0, 800,
and 1500 s/mm2 using a single-shot echo-planar sequence
(TR/TE, 8500/105 ms; FOV, 36 cm; section thickness,
6 mm; no gap; matrix, 128 × 128; NEX, 5; acquisition time,
4 min and 32 s). A dynamic study of both breasts was ob-
tained in an axial plane. A three-dimensional spoiled gra-
dient recalled acquisition in the steady state sequence
(TR/TE/TI [inversion time], 6.0/2.5/18 ms; flip angle, 10°;
FOV, 32 cm; section thickness, 1.8 mm; matrix, 352 × 352;
acquisition time, 1 min and 5 s) was used. Following the
first and second scans in an axial plane after the adminis-
tration of gadopentetate dimeglumine (0.1 mmol/kg body
weight), a third scan in a sagittal plane and a fourth scan
in an axial plane were acquired.
Image analysis
In all cases, MRI was performed a total of three times:
prior to NAC, after the first half of NAC, and after the
completion of NAC. The chief investigator, a radiologist
specializing in breast imaging, performed all breast MRI
examinations. MR images were reviewed without know-
ledge of the clinicopathologic findings. On the MR image
prior to NAC, the margin of the mass, presence of intratu-
moral necrosis, and presence of tumor extension around
the mass were analyzed. The margin of the mass was
roughly divided into two categories: smooth or irregular.
If there was a very high signal intensity (similar to that of
water) in the tumor on fat-suppressed T2-weighted MR
imaging, we judged it to represent intratumoral necrosis.
If there was a similar degree of enhancement around the
mass on dynamic MR images, we judged it to represent
tumor extension. Dynamic contrast medium uptake was
evaluated by relative signal enhancement (RSE) and the
kinetic curve pattern. RSE was calculated using the follow-
ing equation:




The kinetic curve pattern was categorized into three
types (washout, plateau, and persistent) according to the
BI-RADS MR guidelines (American College of Radiology
2003).
Histopathologic assessment
A core biopsy of the tumor was performed prior to NAC
to determine the histological diagnosis. Immunohisto-
chemical staining for estrogen receptor (ER) and proges-
terone receptor (PgR), HER2, and Ki-67 was performed.
Table 2 MRI features according to each intrinsic subtype
LA n-LA LB n-LB LH2 n-LH2 H2 n-H2 TN n-TN
MRI findings (n = 24) (n = 92) (n = 15) (n = 101) (n = 14) (n = 102) (n = 23) (n = 93) (n = 40) (n = 76)
Mass margin
Smooth 7(29) 52(57) 7(47) 52(51) 6(43) 53(52) 15(65)b 44(47) 24(60) 35(46)
Irregular 17(71)a 40(43) 8(53) 49(49) 8(57) 49(48) 8(35) 49(53) 16(40) 41(54)
aP = .005 bP = .032
Intratumoral necrosis
Presence 4(17) 17(18) 3(20) 18(18) 0(0) 21(21) 2(9) 19(20) 12(30)c 9(12)
Absence 20(83) 75(82) 12(80) 83(82) 14(100) 81(79) 21(91) 74(80) 28(70) 67(88)
cP = .019
Tumor extension around mass
Presence 17(71) 69(75) 7(47) 79(78) 10(71) 76(75) 21(91)e 65(70) 31(78) 55(72)
Absence 7(29) 23(25) 8(53)d 22(22) 4(29) 26(25) 2(9) 28(30) 9(22) 21(28)
dP = .0047 eP = .009
Kinetic curve pattern
Washout 5(21) 37(40) 8(53) 34(34) 5(36) 37(36) 14(61) 28(30) 10(25) 32(42)
Plateau 14(58) 44(48) 6(40) 52(51) 8(57) 50(49) 6(26) 52(56) 24(60) 34(45)
Persistent 5(21) 11(12) 1(7) 15(15) 1(7) 15(15) 3(13) 13(14) 6(15) 10(13)
LA luminal A, n-LA non-luminal A, LB luminal B, n-LB non-luminal B, LH2 luminal-HER2, n-LH2 non-luminal-HER2, H2 HER2, n-H2 non-HER2, TN triple-negative,
n-TN non-triple-negative.
a,b,c,d,eIndicates statistical significance (P < .05).
Figure 1 Luminal A breast cancer of right breast in 40-year-old woman. Prior to NAC, dynamic MR images obtained at 60 s (a), 240 s (b),
and 300 s (c) after administration of gadolinium show a persistent enhancing mass with an irregular border. After the completion of NAC,
residual tumor still shows an enhancement on dynamic MR image obtained at 60 s (d).
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Denmark), and scored on a scale from 0 to 3+. Tumors
with scores of ≥3 or with a ≥2.2-fold increase in HER2 gene
amplification as determined by fluorescence in situ hybridi-
zation (FISH) were considered to be positive for HER2
overexpression.
After NAC, all patients underwent either mastectomy
or breast-conserving surgery. Surgical specimens from the
breast-conserving surgeries were cut into 5-mm slices and
those from mastectomies were cut into 5–10 mm slices.
The specimens were stained with hematoxylin and eosin
for histopathological evaluations.
The pathological response following NAC was evaluated
by pathologists according to the Japanese Breast Cancer
Society’s criteria for the assessment of therapeutic response
(The Japanese Breast Cancer Society 2012). Considering
the clinical response, the overall response to chemotherapy
was classified into the following five categories: Grade 3:
no residual invasive cancer; Grade 2b: only a few remain-
ing cancer cells; Grade 2a: marked changes in two-thirds
or more of cancer cells; Grade 1b: marked changes in
one-third or more but less than two-thirds of cancer
cells; Grade 1a: marked changes in less than one-third
of cancer cells.Figure 2 HER2 breast cancer of left breast in 71-year-old woman. Prio
300 s (c) after administration of gadolinium show a strong and washout en
mass is shown in Figure 2b. After the completion of NAC, there is no longeStatistical analysis
MRI features according to each intrinsic subtype were
analyzed using multivariate logistic regression analysis
with the statistical program Stat Flex (version 6, Arthch
Inc., Osaka, Japan). To compare the RSE between each
intrinsic subtype, we used a multiple comparison method
(Dunn’s method). A multiple regression analysis was per-
formed to examine the relationship between the MRI and
immunohistochemical findings with NAC effects. A best-
fit regression model was sought by use of a stepwise
selection method. P-values of < 0.05 were considered
statistically significant.
Results
MRI features according to each intrinsic subtype are shown
in Table 2. An irregular mass margin was significantly as-
sociated with luminal A cancers (P =0.005) (Figure 1) and
a smooth mass margin with HER2 cancers (P =0.032)
(Figure 2). Intratumoral necrosis was significantly associ-
ated with triple-negative cancers (P =0.019) (Figure 3).
Tumor extension around the mass was significantly infre-
quent in luminal B cancers (P =0.0047) and frequent in
HER2 cancers (P =0.009) (Figure 2). No significant charac-
teristics were demonstrated by luminal-HER2 cancers. Asr to NAC, dynamic MR images obtained at 60 s (a), 240 s (b), and
hancing mass with a smooth border. Tumor extension around the
r recognizable tumor on dynamic MR image obtained at 300 s (d).
Figure 3 Triple-negative breast cancer of left breast in 69-year-old woman. Prior to NAC, fat-suppressed T2-weighted MR image shows a
mass with an area of very high intratumoral intensity (a) and dynamic MR image obtained at 60 s after administration of gadolinium shows a
peripherally-enhancing mass with a large area of intratumoral necrosis (b). After the completion of NAC, very high intratumoral intensity enlarges
on fat-suppressed T2-weighted MR image (c) and there is an increase in tumor size on dynamic MR image obtained at 60 s (d).
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showed a persistent pattern, while luminal B and HER2
cancers frequently showed washout patterns. However, the
results were not statistically significant.
RSE according to each intrinsic subtype is shown in
Figures 4 and 5. Luminal B cancers showed a significantly
higher RSE than luminal A cancers (P < 0.01), and HER2
cancers also showed a significantly higher RSE than luminal
A cancers (P < 0.05) at 2 min (Figure 4). RSE at 6 min was
not significantly different between the intrinsic subtypes
(Figure 5).
The pathological response following NAC according to
each intrinsic subtype is shown in Figure 6. HER2 cancers
showed the highest pathological complete response (pCR)
rate (Grade 3); on the other hand, luminal B cancers
showed the lowest pCR rate. A multiple regression ana-
lysis was performed to examine the relationship between
the MRI and immunohistochemical findings with NAC
effects (Table 3). ER-positive cancers (P =0.024), HER2-negative cancers (P =0.022), and presence of intratu-
moral necrosis (P =0.016) were significantly associated
with NAC non-response. PgR and Ki-67 status, margin of
the mass, presence of tumor extension around the mass,
RSE, and kinetic curve pattern were not significantly asso-
ciated with NAC response.
Discussion
The major principles of treatment for breast cancer pa-
tients are standardization and individualization. Namely,
while employing an evidence-based standard treatment
as a foundation, the details of individual treatment pro-
tocols are established based on the level of risk of each
individual patient. Breast cancer is a heterogeneous dis-
ease and it has become clear that breast cancer can be
divided into biologically different intrinsic subtypes by
gene expression analysis (Perou et al. 2000; Sorlie et al.
2001; Perou & Borresen-Dale 2011; Brenton et al. 2005).
Additionally, in clinical care, it is common that the
LA luminal A, LB luminal B, LH2 luminal-HER2, H2 HER2, TN triple-negative
(P < 0.01),       (P < 0.05)        
Figure 4 Relative signal enhancement (RSE) at 2 min according to each intrinsic subtype. Luminal B cancers showed significantly higher
RSE than luminal A cancers (P < 0.01), and HER2 cancers also showed significantly higher RSE than luminal A cancers (P < 0.05).
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munohistochemical technique (Tamimi et al. 2008), and
a therapeutic plan is formed based on each intrinsic sub-
type. Among the several intrinsic subtypes, triple-negative
breast cancer experientially shows characteristic imaging
findings. Uematsu et al. have reported that MRI findings
including a smooth mass margin, rim enhancement, and
very high signal intensity on T2-weighted imaging were
significantly associated with triple-negative breast cancers
compared to ER-positive, PR-positive, and HER2-negative
cancers (Uematsu et al. 2009).
Recently, some reports have shown the evaluation of
the MRI findings of all breast cancer subtypes; however,
few characteristic findings have been revealed, except for
triple-negative breast cancer (Hao et al. 2013; Bae et al.
2014; Yamaguchi et al. 2014). The results of our study
show that an irregular mass margin was significantly as-
sociated with luminal A cancers. Luminal A cancers aregenerally slow-growing and histologically rich in fibrous
components. These characteristics are thought to be a
cause of the irregular mass margin. The tendency toward
a kinetic persistent pattern and low RSE at 2 min in lu-
minal A cancers are also speculated to originate from
the same reason.
In our study, a smooth mass margin and tumor exten-
sion around the mass were significantly associated with
HER2 cancers. The tendency toward a kinetic washout pat-
tern and high RSE at 2 min in HER2 cancers are thought
to reflect the highly proliferative activity of HER2 cancers.
Luminal B cancers also showed a tendency toward a kin-
etic washout pattern and a high RSE at 2 min; however,
tumor extension around the mass was significantly infre-
quent, in contrast to HER2 cancer. As no significant char-
acteristics were demonstrated by luminal-HER2 cancers,
further analysis concerning the differentiation of luminal B
and luminal-HER2 cancers is required.
LA luminal A, LB luminal B, LH2 luminal-HER2, H2 HER2, TN triple-negative
Figure 5 Relative signal enhancement (RSE) at 6 min according to each intrinsic subtype. RSE at 6 min was not significant different
between each intrinsic subtype.
LA luminal A, LB luminal B, LH2 luminal-HER2, H2 HER2, TN triple-negative
Figure 6 Pathological response following NAC according to each intrinsic subtype.
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Table 3 Relationship between NAC effects with the MRI
and immunohistochemical findings by multiple
regression analysis
P value β stdβ
ER .0244 −0.6213 −0.2017
PgR NS
HER2 .0222 0.6885 0.2091
Ki-67 NS
Mass margin NS
Intratumoral necrosis .0157 −0.8826 −0.2214
Tumor extension around mass NS
Kinetic curve pattern NS
RSE 2 min NS
RSE 6 min NS
NAC neoadjuvant chemotherapy, β partial regression coefficient, stdβ standard
partial regression coefficient, ER estrogen receptor, PgR progesterone receptor,
HER2 human epidermal growth factor receptor 2, RSE relative
signal enhancement.
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ings in triple-negative cancers (Kawashima et al. 2011).
In the present study, intratumoral necrosis was signifi-
cantly associated with triple-negative cancers; however,
other imaging findings were not significantly associated.
Further fragmentation of triple-negative cancers by gene
expression analysis has already commenced; therefore,
the methods of imaging analysis are expected to change
in the near future.
As NAC becomes more widespread, there have been
more opportunities to conduct evaluations via diagnostic
imaging. In particular, MRI plays a central role (Rosen
et al. 2003; Partridge et al. 2002; Londero et al. 2004;
Balu-Maestro et al. 2002; Akazawa et al. 2006). MRI has
been proposed to have a role in early response assess-
ment after initiating NAC (Abraham et al. 1996; Yeh
et al. 2005). Contrast-enhanced MRI is known to enable an
accurate assessment of tumor response after NAC (Heldahl
et al. 2011; Liu et al. 2011), and diffusion-weighted MRI is
also helpful in predicting response to NAC (Theilmann
et al. 2004; Thoeny & Ross 2010). Recently, there have
been reports on predictions of treatment effects made by
focusing on the kinetic parameters of dynamic MRI and
predictions of effects using parametric MRI (Abramson
et al. 2013; Jafri et al. 2013; Koo et al. 2012).
The former investigator reported differences in pre-
treatment imaging findings between responders and non-
responders in triple-negative cancers and found that no ef-
fective treatment response can be expected in cases with an
irregular mass shape and intratumoral necrosis (Kawashima
et al. 2011). In the present study, we investigated the cor-
relation between pre-treatment MRI findings and final
NAC effect for all breast cancer subtypes. From the
viewpoint of immunohistochemical status, ER-positiveand HER2-negative cancers were significantly associated
with NAC non-response. This result is compatible with
our clinical experience. Ki-67 status was not significantly
associated with NAC response. This result might be caused
by the small number of cases have measured the Ki-67
labeling index.
Among the MRI findings, only the presence of intra-
tumoral necrosis was significantly associated with NAC
non-response. The margin of the mass, presence of tumor
extension around the mass, RSE, and kinetic curve pattern
were not significantly associated with NAC response. These
results might be caused by the relatively small number of
luminal B and luminal-HER2 cancers in the present study
compared to the other subtypes.
Our study has several limitations. First, we enrolled
patients who were NAC-recipients and who underwent
MRI on the same 3.0 T machine. Therefore, there may be
a bias due to selecting NAC cases and the number of cases
is insufficient. Further studies with larger numbers of cases
are needed. Second, the Ki-67 labeling index was not mea-
sured in patients in the early period of the study. Third, the
presence of tumor extension around the mass on MRI was
not confirmed pathologically. While no definitive conclu-
sions can be made from the present study because of these
limitations, a variety of MRI findings was shown, even
within each intrinsic subtype. Further detailed analysis of
MRI findings in each intrinsic subtype in parallel with the
fragmentation of each intrinsic subtype by gene expression
analysis is expected.
In conclusion, several MR imaging features might be
used to predict the intrinsic subtype of breast cancer. ER-
positive cancers, HER2-negative cancers, and the presence
of intratumoral necrosis were significantly associated with
the NAC non-response.
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